

research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 16:43:03 ON 14 APR 2007

=> file .cherie

COST IN U.S. DOLLARS

SINCE FILE

ENTRY

TOTAL

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'EMBASE' ENTERED AT 16:43:24 ON 14 APR 2007

Copyright (c) 2007 Elsevier B.V. All rights reserved.

FILE 'MEDLINE' ENTERED AT 16:43:24 ON 14 APR 2007

FILE 'CAPLUS' ENTERED AT 16:43:24 ON 14 APR 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'BIOSIS' ENTERED AT 16:43:24 ON 14 APR 2007

Copyright (c) 2007 The Thomson Corporation

FILE 'SCISEARCH' ENTERED AT 16:43:24 ON 14 APR 2007

Copyright (c) 2007 The Thomson Corporation

FILE 'DISSABS' ENTERED AT 16:43:24 ON 14 APR 2007

COPYRIGHT (C) 2007 ProQuest Information and Learning Company; All Rights Reserved.

FILE 'BIOTECHABS' ACCESS NOT AUTHORIZED

FILE 'REGISTRY' ENTERED AT 16:43:24 ON 14 APR 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 American Chemical Society (ACS)

=> s "collectin fusion protein"

L1 4 "COLLECTIN FUSION PROTEIN"

=> s collectin AND TNF AND fusion

L2 3 COLLECTIN AND TNF AND FUSION

=> d l2 1-3

L2 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2004:817923 CAPLUS

DN 141:330784

TI Chimeric proteins comprising Ig Fc domain and receptor ligand-binding domain or ligand receptor-binding domain for treating autoimmune disease, AIDS, transplant rejection and inflammation

IN Walczak, Henning

PA Apogenix Biotechnology A.-G., Germany

SO PCT Int. Appl., 44 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004085478	A2	20041007	WO 2004-EP3239	20040326
	WO 2004085478	A3	20050106		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,				

CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
 RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

AU 2004224122 A1 20041007 AU 2004-224122 20040326
 CA 2520138 A1 20041007 CA 2004-2520138 20040326
 EP 1606318 A2 20051221 EP 2004-723552 20040326

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK

PRAI EP 2003-6949 A 20030326
 WO 2004-EP3239 W 20040326

L2 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2002:10696 CAPLUS

DN 136:68702

TI Analysis of CD154 oligomerization on CD40 signaling using CD154-collectin fusion protein

IN Al-Shamkhani, Aymen; Glennie, Martin

PA Cancer Research Ventures Limited, UK

SO PCT Int. Appl., 63 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2002000893	A1	20020103	WO 2001-GB2810	20010625
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				

CA 2414342 A1 20020103 CA 2001-2414342 20010625

EP 1297160 A1 20030402 EP 2001-945468 20010625

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR

US 2004047873 A1 20040311 US 2003-312374 20031010

PRAI GB 2000-15426 A 20000624

WO 2001-GB2810 W 20010625

RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L2 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2001:435124 CAPLUS

DN 135:45182

TI Multimeric forms of TNF superfamily ligands

IN Kornbluth, Richard S.

PA USA

SO PCT Int. Appl., 73 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------

PI WO 2001042298 A1 20010614 WO 2000-US7380 20000320
W: AU, CA, JP
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL,
PT, SE
CA 2393659 A1 20010614 CA 2000-2393659 20000320
EP 1235853 A1 20020904 EP 2000-919485 20000320
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, FI, CY
AU 785297 B2 20070104 AU 2000-40167 20000320
US 2005158831 A1 20050721 US 2005-87348 20050322
PRAI US 1999-454223 A 19991209
US 1998-111471P P 19981209
WO 2000-US7380 W 20000320
RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> s collectin AND TNFSF AND fusion
L3 1 COLLECTIN AND TNFSF AND FUSION

=> d l3 all

L3 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2001:435124 CAPLUS
DN 135:45182
ED Entered STN: 15 Jun 2001
TI Multimeric forms of TNF superfamily ligands
IN Kornbluth, Richard S.
PA USA
SO PCT Int. Appl., 73 pp.
CODEN: PIXXD2
DT Patent
LA English
IC ICM C07K014-00
ICS A61K038-00
CC 15-2 (Immunochemistry)
Section cross-reference(s): 3
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001042298	A1	20010614	WO 2000-US7380	20000320
	W: AU, CA, JP				
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	CA 2393659	A1	20010614	CA 2000-2393659	20000320
	EP 1235853	A1	20020904	EP 2000-919485	20000320
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY				
	AU 785297	B2	20070104	AU 2000-40167	20000320
	US 2005158831	A1	20050721	US 2005-87348	20050322
PRAI	US 1999-454223	A	19991209		
	US 1998-111471P	P	19981209		
	WO 2000-US7380	W	20000320		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2001042298	ICM	C07K014-00
	ICS	A61K038-00
	IPCI	C07K0014-00 [ICM,7]; A61K0038-00 [ICS,7]
	IPCR	A61K0039-00 [N,C*]; A61K0039-00 [N,A]; C07K0014-435 [I,C*]; C07K0014-525 [I,A]; C07K0014-705 [I,A]
	ECLA	C07K014/525; C07K014/705Q
CA 2393659	IPCI	C12N0015-09 [ICM,7]; A61K0038-00 [ICS,7]; C07K0014-00 [ICS,7]; C07K0019-00 [ICS,7]
	IPCR	A61K0039-00 [N,C*]; A61K0039-00 [N,A]; C07K0014-435

EP 1235853 IPCI [I,C*]; C07K0014-525 [I,A]; C07K0014-705 [I,A]
 IPCR C07K0014-00 [ICM,6]; A61K0038-00 [ICS,6]
 AU 785297 IPCI A61K0039-00 [N,C*]; A61K0039-00 [N,A]; C07K0014-435
 [I,C*]; C07K0014-525 [I,A]; C07K0014-705 [I,A]
 ECLA C07K014/525; C07K014/705Q
 US 2005158831 IPCI C12P0021-02 [ICM,7]; C07H0021-04 [ICS,7]; C07H0021-00
 [ICS,7,C*]; C07K0014-525 [ICS,7]; C07K0014-435
 [ICS,7,C*]; C12N0001-21 [ICS,7]; C12N0015-74 [ICS,7]
 IPCR A61K0039-00 [N,C*]; A61K0039-00 [N,A]; C07K0014-435
 [I,C*]; C07K0014-525 [I,A]; C07K0014-705 [I,A]
 NCL 435/069.500; 435/252.300; 435/320.100; 530/351.000;
 536/023.500
 ECLA C07K014/525; C07K014/705Q

AB A method for constructing stable bioactive fusion proteins of
 the difficult to express tumor necrosis factor superfamily (TNFSF
), and particularly members CD40L (CD154) and RANKL/TRANCE, with
 collectins, particularly pulmonary surfactant protein D (SPD) is
 described. Single trimers of these proteins lack the full stimulatory
 efficacy of the natural membrane forms of these proteins in many cases.
 The multimeric nature of these soluble fusion proteins enables them
 to engage multiple receptors on the responding cells, thereby, mimicking
 the effects of the membrane forms of these ligands. For CD40L-SPD, the
 resulting protein stimulates B cells, macrophages, and dendritic cells,
 indicating its potential usefulness as a vaccine adjuvant. The large size
 of these fusion proteins makes them less likely to diffuse into
 the circulation, thereby limiting their potential systemic toxicity. This
 property may be especially useful when these proteins are injected locally as a
 vaccine adjuvant or tumor immunotherapy agent to prevent them from
 diffusing away. In addition, these and other TNFSF-collecting
 fusion proteins present new possibilities for the expression of
 highly active, multimeric, soluble TNFSF members.

ST vaccine adjuvant fusion protein CD40L RANKL TRANCE; tumor
 immunotherapeutic TNF collectin fusion protein;
 pulmonary surfactant protein D TNF CD40L

IT Glycoproteins, specific or class
 RL: BPN (Biosynthetic preparation); PRP (Properties); THU (Therapeutic
 use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (CD40-L (antigen CD40 ligand), fusion protein; multimeric
 forms of TNF superfamily ligands as tumor immunotherapeutic agents)

IT Antigens
 RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)
 (OX-40, ligand or TNFSF4; multimeric forms of TNF superfamily ligands
 as tumor immunotherapeutic agents)

IT Cytokines
 RL: BPN (Biosynthetic preparation); PRP (Properties); THU (Therapeutic
 use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (RANKL/TRANCE; multimeric forms of TNF superfamily ligands as tumor
 immunotherapeutic agents)

IT Surfactant proteins (pulmonary)
 RL: BPN (Biosynthetic preparation); PRP (Properties); THU (Therapeutic
 use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (SP-D, fusion protein; multimeric forms of TNF superfamily
 ligands as tumor immunotherapeutic agents)

IT Tumor necrosis factors
 RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)
 (TNFSF18 or AITRL or GITRL; multimeric forms of TNF superfamily ligands
 as tumor immunotherapeutic agents)

IT Tumor necrosis factors
 RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)
 (TNFSF2; multimeric forms of TNF superfamily ligands as tumor

immunotherapeutic agents)

IT Tumor necrosis factors
 RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (TNFSF4 or OX-40 ligand; multimeric forms of TNF superfamily ligands as tumor immunotherapeutic agents)

IT Immunostimulants
 (adjuvants; multimeric forms of TNF superfamily ligands as tumor immunotherapeutic agents)

IT Neoplasm
 (cells; multimeric forms of TNF superfamily ligands as tumor immunotherapeutic agents)

IT Agglutinins and Lectins
 RL: BPN (Biosynthetic preparation); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (collectins, fusion protein; multimeric forms of TNF superfamily ligands as tumor immunotherapeutic agents)

IT Lymphocyte
 (immunocompetent; multimeric forms of TNF superfamily ligands as tumor immunotherapeutic agents)

IT Human immunodeficiency virus
 (infected cells; multimeric forms of TNF superfamily ligands as tumor immunotherapeutic agents)

IT Proteins, general, biological studies
 RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (mammalian; multimeric forms of TNF superfamily ligands as tumor immunotherapeutic agents)

IT Alfalfa (*Medicago sativa*)
 Animal
 Antitumor agents
 B cell (lymphocyte)
 DNA sequences
 Dendritic cell
Escherichia coli
 Eukaryote (Eukaryotae)
 Genetic vectors
 Immunotherapy
 Macrophage
 Mammal (Mammalia)
 Molecular cloning
 Plant (Embryophyta)
 Prokaryote
 Protein sequences
Saccharomyces cerevisiae
 Tobacco
 Vaccines
 Yeast
 (multimeric forms of TNF superfamily ligands as tumor immunotherapeutic agents)

IT Fusion proteins (chimeric proteins)
 RL: BPN (Biosynthetic preparation); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (multimeric forms of TNF superfamily ligands as tumor immunotherapeutic agents)

IT Lymphotoxin
 RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (multimeric forms of TNF superfamily ligands as tumor immunotherapeutic agents)

IT Animal cell
 (multiple receptors; multimeric forms of TNF superfamily ligands as tumor immunotherapeutic agents)

IT Receptors
 RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL

(Biological study); PROC (Process)
(multiple; multimeric forms of TNF superfamily ligands as tumor immunotherapeutic agents)

IT Gene
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(open reading frame; multimeric forms of TNF superfamily ligands as tumor immunotherapeutic agents)

IT DNA
RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(recombinant; multimeric forms of TNF superfamily ligands as tumor immunotherapeutic agents)

IT Genetic element
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(signal sequence, secretory; multimeric forms of TNF superfamily ligands as tumor immunotherapeutic agents)

IT Gene, animal
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(structural; multimeric forms of TNF superfamily ligands as tumor immunotherapeutic agents)

IT Tumor necrosis factors
RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(superfamily; fusion proteins; multimeric forms of TNF superfamily ligands as tumor immunotherapeutic agents)

IT Promoter (genetic element)
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(transcriptional; multimeric forms of TNF superfamily ligands as tumor immunotherapeutic agents)

IT Vaccines
(tumor; multimeric forms of TNF superfamily ligands as tumor immunotherapeutic agents)

IT Antitumor agents
(vaccines; multimeric forms of TNF superfamily ligands as tumor immunotherapeutic agents)

IT Lymphotoxin
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(β ; multimeric forms of TNF superfamily ligands as tumor immunotherapeutic agents)

IT 344972-84-5 344972-85-6 344972-86-7
RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(amino acid sequence; multimeric forms of TNF superfamily ligands as tumor immunotherapeutic agents)

IT 139808-69-8P, GenBank X01393 140063-18-9P, GenBank D90224
147458-39-7P, GenBank L11016 148141-97-3P, GenBank X02910
149769-18-6P, GenBank L09753 224557-16-8P, GenBank AF125303
RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(multimeric forms of TNF superfamily ligands as tumor immunotherapeutic agents)

IT 344972-87-8 344972-88-9 344972-89-0
RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(nucleotide sequence; multimeric forms of TNF superfamily ligands as tumor immunotherapeutic agents)

IT 344974-43-2 344974-44-3 344974-45-4 344974-46-5 344974-47-6

344974-48-7 344974-49-8 344974-50-1 344974-51-2 344974-52-3
344974-53-4 344974-54-5 344974-55-6

RL: PRP (Properties)

(unclaimed sequence; multimeric forms of TNF superfamily ligands)

RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

(1) Gires, O; EMBO J 1999, V16(20), P6131

(2) Pison, U; Eur J Clin Inv 1994, V24(9), P586 CAPLUS

=> s collectin AND TNFSF

L4 1 COLLECTIN AND TNFSF

=> d 14 all

L4 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2001:435124 CAPLUS

DN 135:45182

ED Entered STN: 15 Jun 2001

TI Multimeric forms of TNF superfamily ligands

IN Kornbluth, Richard S.

PA USA

SO PCT Int. Appl., 73 pp.

CODEN: PIXXD2

DT Patent

LA English

IC ICM C07K014-00

ICS A61K038-00

CC 15-2 (Immunochemistry)

Section cross-reference(s): 3

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001042298	A1	20010614	WO 2000-US7380	20000320
	W: AU, CA, JP				
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	CA 2393659	A1	20010614	CA 2000-2393659	20000320
	EP 1235853	A1	20020904	EP 2000-919485	20000320
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY				
	AU 785297	B2	20070104	AU 2000-40167	20000320
	US 2005158831	A1	20050721	US 2005-87348	20050322
PRAI	US 1999-454223	A	19991209		
	US 1998-111471P	P	19981209		
	WO 2000-US7380	W	20000320		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2001042298	ICM	C07K014-00
	ICS	A61K038-00
	IPCI	C07K0014-00 [ICM,7]; A61K0038-00 [ICS,7]
	IPCR	A61K0039-00 [N,C*]; A61K0039-00 [N,A]; C07K0014-435 [I,C*]; C07K0014-525 [I,A]; C07K0014-705 [I,A]
	ECLA	C07K014/525; C07K014/705Q
CA 2393659	IPCI	C12N0015-09 [ICM,7]; A61K0038-00 [ICS,7]; C07K0014-00 [ICS,7]; C07K0019-00 [ICS,7]
	IPCR	A61K0039-00 [N,C*]; A61K0039-00 [N,A]; C07K0014-435 [I,C*]; C07K0014-525 [I,A]; C07K0014-705 [I,A]
EP 1235853	IPCI	C07K0014-00 [ICM,6]; A61K0038-00 [ICS,6]
	IPCR	A61K0039-00 [N,C*]; A61K0039-00 [N,A]; C07K0014-435 [I,C*]; C07K0014-525 [I,A]; C07K0014-705 [I,A]
AU 785297	IPCI	C07K0014-435 [I,C*]; A61K0039-00 [I,C*]; C07K0014-525 [I,A]; A61K0039-00 [I,A]; C07K0014-705 [I,A]
	ECLA	C07K014/525; C07K014/705Q

US 2005158831 IPCI C12P0021-02 [ICM,7]; C07H0021-04 [ICS,7]; C07H0021-00 [ICS,7,C*]; C07K0014-525 [ICS,7]; C07K0014-435 [ICS,7,C*]; C12N0001-21 [ICS,7]; C12N0015-74 [ICS,7]

IPCR A61K0039-00 [N,C*]; A61K0039-00 [N,A]; C07K0014-435 [I,C*]; C07K0014-525 [I,A]; C07K0014-705 [I,A]

NCL 435/069.500; 435/252.300; 435/320.100; 530/351.000; 536/023.500

ECLA C07K014/525; C07K014/705Q

AB A method for constructing stable bioactive fusion proteins of the difficult to express tumor necrosis factor superfamily (TNFSF), and particularly members CD40L (CD154) and RANKL/TRANCE, with collectins, particularly pulmonary surfactant protein D (SPD) is described. Single trimers of these proteins lack the full stimulatory efficacy of the natural membrane forms of these proteins in many cases. The multimeric nature of these soluble fusion proteins enables them to engage multiple receptors on the responding cells, thereby, mimicking the effects of the membrane forms of these ligands. For CD40L-SPD, the resulting protein stimulates B cells, macrophages, and dendritic cells, indicating its potential usefulness as a vaccine adjuvant. The large size of these fusion proteins makes them less likely to diffuse into the circulation, thereby limiting their potential systemic toxicity. This property may be especially useful when these proteins are injected locally as a vaccine adjuvant

or tumor immunotherapy agent to prevent them from diffusing away. In addition, these and other TNFSF-collecting fusion proteins present new possibilities for the expression of highly active, multimeric, soluble TNFSF members.

ST vaccine adjuvant fusion protein CD40L RANKL TRANCE; tumor immunotherapeutic TNF collectin fusion protein; pulmonary surfactant protein D TNF CD40L

IT Glycoproteins, specific or class
 RL: BPN (Biosynthetic preparation); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (CD40-L (antigen CD40 ligand), fusion protein; multimeric forms of TNF superfamily ligands as tumor immunotherapeutic agents)

IT Antigens
 RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (OX-40, ligand or TNFSF4; multimeric forms of TNF superfamily ligands as tumor immunotherapeutic agents)

IT Cytokines
 RL: BPN (Biosynthetic preparation); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (RANKL/TRANCE; multimeric forms of TNF superfamily ligands as tumor immunotherapeutic agents)

IT Surfactant proteins (pulmonary)
 RL: BPN (Biosynthetic preparation); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (SP-D, fusion protein; multimeric forms of TNF superfamily ligands as tumor immunotherapeutic agents)

IT Tumor necrosis factors
 RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (TNFSF18 or AITRL or GITRL; multimeric forms of TNF superfamily ligands as tumor immunotherapeutic agents)

IT Tumor necrosis factors
 RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (TNFSF2; multimeric forms of TNF superfamily ligands as tumor immunotherapeutic agents)

IT Tumor necrosis factors
 RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (TNFSF4 or OX-40 ligand; multimeric forms of TNF superfamily ligands as tumor immunotherapeutic agents)

IT Immunostimulants
 (adjuvants; multimeric forms of TNF superfamily ligands as tumor immunotherapeutic agents)

IT Neoplasm
 (cells; multimeric forms of TNF superfamily ligands as tumor immunotherapeutic agents)

IT Agglutinins and Lectins
 RL: BPN (Biosynthetic preparation); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (collectins, fusion protein; multimeric forms of TNF superfamily ligands as tumor immunotherapeutic agents)

IT Lymphocyte
 (immunocompetent; multimeric forms of TNF superfamily ligands as tumor immunotherapeutic agents)

IT Human immunodeficiency virus
 (infected cells; multimeric forms of TNF superfamily ligands as tumor immunotherapeutic agents)

IT Proteins, general, biological studies
 RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (mammalian; multimeric forms of TNF superfamily ligands as tumor immunotherapeutic agents)

IT Alfalfa (*Medicago sativa*)
 Animal
 Antitumor agents
 B cell (lymphocyte)
 DNA sequences
 Dendritic cell
 Escherichia coli
 Eukaryote (Eukaryotae)
 Genetic vectors
 Immunotherapy
 Macrophage
 Mammal (Mammalia)
 Molecular cloning
 Plant (Embryophyta)
 Prokaryote
 Protein sequences
 Saccharomyces cerevisiae
 Tobacco
 Vaccines
 Yeast
 (multimeric forms of TNF superfamily ligands as tumor immunotherapeutic agents)

IT Fusion proteins (chimeric proteins)
 RL: BPN (Biosynthetic preparation); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (multimeric forms of TNF superfamily ligands as tumor immunotherapeutic agents)

IT Lymphotoxin
 RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (multimeric forms of TNF superfamily ligands as tumor immunotherapeutic agents)

IT Animal cell
 (multiple receptors; multimeric forms of TNF superfamily ligands as tumor immunotherapeutic agents)

IT Receptors
 RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
 (multiple; multimeric forms of TNF superfamily ligands as tumor immunotherapeutic agents)

IT Gene
 RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(open reading frame; multimeric forms of TNF superfamily ligands as tumor immunotherapeutic agents)

IT DNA
 RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (recombinant; multimeric forms of TNF superfamily ligands as tumor immunotherapeutic agents)

IT Genetic element
 RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (signal sequence, secretory; multimeric forms of TNF superfamily ligands as tumor immunotherapeutic agents)

IT Gene, animal
 RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (structural; multimeric forms of TNF superfamily ligands as tumor immunotherapeutic agents)

IT Tumor necrosis factors
 RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (superfamily; fusion proteins; multimeric forms of TNF superfamily ligands as tumor immunotherapeutic agents)

IT Promoter (genetic element)
 RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (transcriptional; multimeric forms of TNF superfamily ligands as tumor immunotherapeutic agents)

IT Vaccines
 (tumor; multimeric forms of TNF superfamily ligands as tumor immunotherapeutic agents)

IT Antitumor agents
 (vaccines; multimeric forms of TNF superfamily ligands as tumor immunotherapeutic agents)

IT Lymphotoxin
 RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (β ; multimeric forms of TNF superfamily ligands as tumor immunotherapeutic agents)

IT 344972-84-5 344972-85-6 344972-86-7
 RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
 (amino acid sequence; multimeric forms of TNF superfamily ligands as tumor immunotherapeutic agents)

IT 139808-69-8P, GenBank X01393 140063-18-9P, GenBank D90224
 147458-39-7P, GenBank L11016 148141-97-3P, GenBank X02910
 149769-18-6P, GenBank L09753 224557-16-8P, GenBank AF125303
 RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (multimeric forms of TNF superfamily ligands as tumor immunotherapeutic agents)

IT 344972-87-8 344972-88-9 344972-89-0
 RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
 (nucleotide sequence; multimeric forms of TNF superfamily ligands as tumor immunotherapeutic agents)

IT 344974-43-2 344974-44-3 344974-45-4 344974-46-5 344974-47-6
 344974-48-7 344974-49-8 344974-50-1 344974-51-2 344974-52-3
 344974-53-4 344974-54-5 344974-55-6
 RL: PRP (Properties)
 (unclaimed sequence; multimeric forms of TNF superfamily ligands)

RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

- (1) Gires, O; EMBO J 1999, V16(20), P6131
(2) Pison, U; Eur J Clin Inv 1994, V24(9), P586 CAPLUS

=> d his

(FILE 'HOME' ENTERED AT 16:43:03 ON 14 APR 2007)

FILE 'EMBASE, MEDLINE, CAPLUS, BIOSIS, SCISEARCH, DISSABS, REGISTRY'
ENTERED AT 16:43:24 ON 14 APR 2007

L1 4 S "COLLECTIN FUSION PROTEIN"
L2 3 S COLLECTIN AND TNF AND FUSION
L3 1 S COLLECTIN AND TNFSF AND FUSION
L4 1 S COLLECTIN AND TNFSF

=>

---Logging off of STN---

=>

Executing the logoff script...

=> LOG Y

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	93.17	93.38
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-1.56	-1.56

STN INTERNATIONAL LOGOFF AT 16:46:29 ON 14 APR 2007